Genticel develops therapeutic vaccines for women already infected by the human papillomavirus (HPV) before high grade lesions or cervical cancer occur.

The World Health Organization estimated recently that world-wide, 300 million women are carriers of HPV.

Of these, about 93 million women are infected with HPV16 and/or HPV18 types, two HPV types that cause most cancers.

5 million of these women will develop dangerous pre-cancer. Despite prevention and treatment schemes, 350,000 HPV 16+ or HPV18+ patients are still diagnosed with cervical cancer each year.

The company focuses its efforts exclusively on preventing progression of HPV-originating diseases. This is made possible through Genticel's unique therapeutic vaccine platform.